Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-852-1 | CAS number: 26628-22-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Referenceopen allclose all
- Reference Type:
- review article or handbook
- Title:
- Recommendation from the Scientific Committee on Occupational Exposure Limits (SCOEL) for Sodium Azide
- Author:
- Anonymous
- Year:
- 2 008
- Bibliographic source:
- European Commission: Scientific Committee on Occupational Exposure Limits (SCOEL)
- Reference Type:
- publication
- Title:
- Maternal and developmental toxicity study of sodium azide in rats
- Author:
- Faqi A.S. et al.
- Year:
- 2 008
- Bibliographic source:
- Regul Toxicol Pharmacol. 52(2):158-62.
- Reference Type:
- review article or handbook
- Title:
- Weight of Evidence Discussion for Sodium Azide (NaN3)
- Author:
- Mc Carroll N.
- Year:
- 2 007
- Bibliographic source:
- US Environmental Protection Agency (EPA) Memorandum TXR 0054719
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Sodium azide
- EC Number:
- 247-852-1
- EC Name:
- Sodium azide
- Cas Number:
- 26628-22-8
- Molecular formula:
- N3Na
- IUPAC Name:
- sodium azide
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Sodium azide
- Analytical purity: no data
- Impurities (identity and concentrations): no data
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Portage, Michigan, USA
- Age at study initiation: 8-10 weeks
- Weight at study initiation: 208-210 g mean body weight
- Fasting period before study:
- Housing: individually in suspended, stainless steel, wire-mash type cages in an environmentally controlled room.
- Diet (e.g. ad libitum): Lab Diet Certified Rodent Diet #5002, PMI Nutrition International Inc., ad libitum
- Water (e.g. ad libitum): no data
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-26 °C
- Humidity (%): 30-70%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: distilled water, buffered to pH 9.5 with NaOH
- Details on exposure:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): not given
- Concentration in vehicle: 0 mg/kg
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant
- Duration of treatment / exposure:
- Control and test article administration began on GD 6 and continued to include GD 19 for all animals. The test article was administered to the treated groups by oral gavage once per day at approximately the same time each day at dosage levels of 1, 5, and 17.5 mg/kg/bw/day at a dosage volume of 5 mL/kg based on the body weight. From GD 10-12, surviving animals at 17.5 mg/kg bw/day began receiving a reduced dosage level of 10 mg/kg bw/day at a dosage volume of 2.86 mL/kg.
The control animals received the vehicle, distilled water (buffered at pH 9.5 with sodium hydroxide), at a volume of 5 mL/kg and dosing regimen as the treated animals. - Frequency of treatment:
- once a day
- Duration of test:
- gestation day (GD) 6 to 19: 13 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- control
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Remarks:
- low dose
- Dose / conc.:
- 5 mg/kg bw/day (nominal)
- Remarks:
- mid dose
- Dose / conc.:
- 17.5 mg/kg bw/day (nominal)
- Remarks:
- high dose
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The highest dose was selected based on 90-day oral gavage study in rats (NCI, 1981). In this study nearly total mortality occurred at the 20 mg/kg dose over the experimental period, but no deaths occurred at other doses including 10 mg/kg bw/day. Of the total females in the study, two females died in each week 2, and 6 and six females died on Week 7 of the study. In males the death occurred between weeks 7 and 13 of the study. As the mortality effect observed at 20 mg/kg bw/day in the NCI (1981) study was over a longer period, and while the duration of the current study was only 14 days; it was decided that a 17.5 mg/kg bw/day would be appropriate for use as the highest dose in this study. Then, the high-dose (17.5 mg/kg bw/day) was reduced to 10 mg/kg/day due to severe maternal mortality.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: not given
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: not given
BODY WEIGHT: Yes
- Time schedule for examinations: not given
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
- Organs examined: complete necropsy including uterine examination - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Number of live and dead fetuses - Fetal examinations:
- - External examinations: Yes: [all per litter]
- Soft tissue examinations: No data
- Skeletal examinations: Yes: [half per litter]
- Head examinations: No
- Visceral examinations: Yes: [half per litter] - Statistics:
- Mean and SDs were calculated for all measured parameters. Gestation body weights, gestation body weight gains, and gestation food consumption were analyzed by ANOVA followed, where appropriate, by Dunnett's test. Comparison of litter (fetal) body weight data was analyzed by ANOVA; the litter was the unit of observation. For reproductive parameters, a one factor (i.e. treatment group) ANOVA was used for mean corpora lutea, mean total, live and non-live (resorptions and death) implants, mean percent live and non-live implants, and mean percent preand post implantation loss. Visceral and skeletal data were analyzed by Fisher's Exact Test. Sex ratio (% male/litter) was transformed using Arcsin square-root transformation. The transformed data was then analyzed using Dunnett's adjusted t-test and or Welch's f-test with a Bonferroni correction as appropriate. A minimum significance level of p = 0.05 was used for all comparisons.
- Indices:
- no data
- Historical control data:
- The mean values of implantation sites and mean viable fetuses at 17.5/10 mg/kg bw/day were within the laboratory's historical background of the species of rats used in the study.
No data on comparison of other treatment groups to historical controls are made.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- For more details see "details on results" section below.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- For more details see "details on results" section below.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- For more details see "details on results" section below.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- For more details see "details on results" section below.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- A total of 20 out of 25 dams in the high-dose group (17.5 mg/kg bw/day) died between GD 8 and GD 10. From GD 10-12, the dosage level for the surviving animals (n = 5) was then reduced to 10 mg/kg bw/day. Two out of the 5 surviving animals died after the dose was reduced to 10 mg/kg bw/day. All the animals died between GD 8 and GD 12 of the study. No death was observed in the low- (1 mg/kg bw/day) and mid-dose group (5 mg/kg bw/day).
Treatment-related clinical signs of toxicity were observed in the high-dose group (17.5/10 mg/kg bw/day), which included decreased activity, prostration, loss of righting reflex, lacrimation, impaired limb function, swelling (head and face), moribundity, and difficult/slow/shallow breathing. Although the mortality was sodium azide induced, no sodium azide-related macroscopic lesions were observed in dams at necropsy.
Gestation body weight and gestation body weight changes were significantly decreased in the animals receiving the high-dose (17.5/10 mg/kg bw/day; Tables 1 and 2) when compared to the control animals. Gestation body weight and gestation body weight changes were not affected in the animals receiving 1 and 5 mg/kg bw/day. Similarly, gestation food consumption was significantly impacted in the animals of the high-dose group (Table 3). Corrected final GD 20 body weight and corrected weight change (GD 0-20) were significantly decreased at 17.5/10 mg/kg bw/day in comparison to the control animals.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Description (incidence and severity):
- For more details see "details on maternal toxic effects" section below.
- Total litter losses by resorption:
- not specified
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- effects observed, treatment-related
- Description (incidence and severity):
- For more details see "details on maternal toxic effects" section below.
- Changes in pregnancy duration:
- not specified
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- The pregnancy index was 96% in the control and 100% in the treatment groups. A total of 22 animals died at 17.5/10 mg/kg bw/day. Resultant number of dams with viable fetuses at GD 20 was 24, 25, 25, and 3 in the control, 1 mg/kg bw/day, 5 mg/kg bw/day, and 17.5 /10 mg/kg bw/day groups, respectively. Implantation sites, viable fetuses, and litter size per dam were significantly higher in the high-dose group (17.5/10 mg/kg bw/day) in comparison to the control group. This was not considered to be sodium azide-related, as comparison to the control is difficult due to the small number of surviving dams (n = 3) available on GD 20 for this group. All the other uterine parameters examined during the study were comparable among the groups.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 17.5 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Remarks on result:
- other: At days 10-12, high-dose (17.5 mg/kg bw/day) was reduced to 10 mg/kg/day due to severe maternal mortality
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- For more details see "details on embryotoxic/teratogenic effects" section below.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- not examined
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Fetal body weights were significantly affected in the three remaining litters at 17.5/10 mg/kg bw/day.However, no effects of treatment were evident from fetal external, visceral or skeletal examinations at any of the dose levels evaluated.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 17.5 mg/kg bw/day (nominal)
- Basis for effect level:
- fetal/pup body weight changes
- Remarks on result:
- other: At days 10-12, high-dose (17.5 mg/kg bw/day) was reduced to 10 mg/kg/day due to severe maternal mortality
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- no
Any other information on results incl. tables
Table 1: Gestation body weight (g)
Gestation days |
Control |
1 mg/kg bw/day |
5 mg/kg bw/day |
17.5 mg/kg bw/day |
0 |
207.9 ± 13.5 |
208.9 ± 10.7 |
210.5 ± 11.8 |
209.6 ± 11.8 |
6 |
250.0 ± 15.8 |
248.3 ± 12.5 |
249.5 ± 13.1 |
249.6 ± 14.3 |
9 |
266.3 ± 18.0 |
262.7 ± 13.5 |
265.6 ± 14.1 |
247.8 ± 17.4** |
12 |
282.8 ± 12.3 |
280.3 ± 15.7 |
282.8 ± 13.7 |
219.1 ± 32.6** |
15 |
301 ± 22.5 |
301.4 ± 18.1 |
302.7 ± 15.7 |
248.7 ± 39.1** |
18 |
338.7 ± 25.2 |
337.6 ± 25.2 |
339.8 ± 18.1 |
295.1 ± 53.7* |
20 |
371.6 ± 27.2 |
370.6 ± 27.7 |
374.2 ± 20.2 |
326.5 ±42.1* |
Note:
Data are means ± SD; from GD 10-12, the high-dose was reduced to 10
mg/kg bw/day;
n = corresponds to the number of animals.
* Significantly different from control (p < 0.05)
** Significantly different from control (p < 0.01)
Table 2: Gestation body weight gain (g)
Gestation interval (days) |
Control |
1 mg/kg bw/day |
5 mg/kg bw/day |
17.5 mg/kg bw/day |
0-6 |
42.1 ± 6.5 |
39.3 ± 7.9 |
39.0 ± 5.8 |
40.1 ± 6.2 (n = 25) |
6-9 |
16.3 ± 5.6 |
14.4 ± 4.9 |
16.1 ± 6.0 |
-1.6 ± 11.4** |
9-12 |
16.59 ± 5.2 |
17.6 ± 6.5 |
17.2 ± 4.0 |
-27.0 ± 15.2** |
12-15 |
18.2 ± 7.8 |
21.1 ± 5.7 |
19.9 ± 5.5 |
16.6± 15.9 |
15-18 |
37.7 ± 7.9 |
36.2 ± 10.4 |
37.0 ± 6.6 |
46.4 ± 15.4 |
18-20 |
32.9 ± 6.5 |
33.0 ± 5.2 |
34.4 ± 5.2 |
31.4± 12.3 |
6-20 |
121.6 ± 16.8 |
122.3 ± 19.7 |
124.7 ± 16.4 |
79.8 ± 15.7** |
0-20 |
163.7 ± 19.5 |
161.6 ±23.7 |
163.7 ± 17.0 |
122.0 ± 17.9** |
Note:
Data are means ± SD; from GD 10-12, the high-dose was reduced to 10
mg/kg bw/day;
n = corresponds to the number of animals.
** Significantly different from control (p < 0.01)
Table 3: Gestation food consumption (g)
Gestation interval (days) |
Control |
1 mg/kg bw/day |
5 mg/kg bw/day |
17.5 mg/kg bw/day |
0-6 |
19.9 ± 3.0 |
20.7 ± 1.8 |
21.0 ± 2.4 |
20.7 ± 1.5 |
6-9 |
23.6 ± 2.8 |
22.8 ± 2.1 |
22.6 ± 3.3 |
15.7 ± 5.9** |
9-12 |
24.4 ± 2.2 |
24.0 ± 2.4 |
24.6 ± 1.9 |
9.1 ± 4.4** |
12-15 |
25.1 ± 3.5 |
26.1 ± 2.5 |
25.5 ± 3.4 |
14.7 ± 4.2** |
15-18 |
27.9 ± 2.8 |
27.5 ± 3.6 |
27.5 ± 2.8 |
23.6 ± 5.7 |
18-20 |
28.6 ± 3.9 |
27.9 ± 3.2 |
28.3 ± 2.4 |
26.2 ± 0.8 |
6-20 |
25.7 ± 2.1 |
25.5 ± 2.5 |
25.6 ± 2.1 |
17.9 ± 1.9** |
0-20 |
23.9 ± 2.1 |
24.0 ± 2.2 |
24.3 ± 2.0 |
18.3 ± 1.0** |
Note:
Data are means ± SD; from GD 10-12, the high-dose was reduced to 10
mg/kg bw/day;
n = corresponds to the number of animals.
** Significantly different from control (p < 0.01)
Table 4: Summary of maternal and uterine data
Endpoints |
Control |
1 mg/kg bw/day |
5 mg/kg bw/day |
17.5 mg/kg bw/day |
No. females on study |
25 |
25 |
25 |
25 |
Number pregnant |
24 |
25 |
25 |
25 |
Number not pregnant |
1 |
0 |
0 |
0 |
Pregnancy index (%) |
96 |
100 |
100 |
100 |
Number died pregnant |
0 |
0 |
0 |
22 |
Number females with viable fetuses |
24 |
25 |
25 |
3 |
Number of corpora lutea/animal |
13.0 ± 1.85 |
13.6 ± 1.82 |
13.9 ± 1.87 |
13.9 ± 1.87 |
Implantation sites per animal |
12.2 ± 1.55 |
12.6 ± 1.58 |
13.1 ±2.31 |
15.0 ± 1.73* |
Pre-implantation loss per animal |
10.84 ± 10.460 |
7.49 ± 7.897 |
5.87 ± 12.795 |
4.07 ± 3.572 |
Viable fetuses per animal |
11.7 ± 1.65 |
12.0 ± 1.70 |
12.8 ± 2.38 |
14.7 ± 2.08* |
Post-implantation loss (% implants per animal) |
3.77 ± 5.728 |
4.11 ±6.499 |
2.22 ± 3.710 |
2.38 ± 4.124 |
Nonviable fetuses/animal |
0.0 ± 0.0 |
0.0 ± 0.0 |
0.0 ± 0.0 |
0.0 ± 0.0 |
Resorptions (early + late) |
0.5 ± 0.7 |
0.5 ± 0.8 |
0.3 ± 0.5 |
0.3 ± 0.6 |
|
|
|
|
|
Fetal weight (g) |
|
|
|
|
Male (M) |
4.08 ± 0.250 |
4.13 ± 0.286 |
4.10 ± 0.293 |
3.57 ± 0.269 |
Female (F) |
3.89 ± 0.263 |
3.88 ± 0.289 |
3.88 ± 0.245 |
3.36 ± 0.224* |
Combined (M + F) |
3.89 ± 0.263 |
4.01 ± 0.273 |
4.00 ± 0.251 |
3.44 ± 0.203* |
Sex ratio (mean % of males/litter) |
50.8 ± 15.8 |
55.8 ± 15.7 |
44.8 ± 12.3 |
45.4 ± 24.2 |
Note:
Data are means ± SD
n = corresponds to the number of litters examined; from GD 10-12, the
high-dose was reduced to 10 mg/kg bw/day.
* Significantly different from control (p < 0.05).
Applicant's summary and conclusion
- Conclusions:
- Overt maternal and developmental toxicity was observed at a dosage level of 17.5/10 mg/kg bw/day, which can be considered as LOAEL. No adverse effects were observed in the lower dose groups and therefore the NOAEL is considered to be 5 mg/kg bw/day. The decrease in fetal weight at the highest dose coincided with maternal signs of clinical toxicity, therefore sodium azide does not have an effect on the development of the fetuses.
- Executive summary:
In a developmental toxicity study (equivalent to OECD Guideline 414) sodium azide was administered to 25 sperm-positive SD rats/dose by gavageat dose levels of 0, 1, 5, or 17.5 mg/kg bw/day from days 6 through 19 of gestation (GD). From GD 10 -12, the high-dose was reduced to 10 mg/kg bw/day due to maternal mortality. Cesarean section was performed on GD 20 and implantation and resorption sites, live and dead fetuses were counted. Fetuses were weighed, sexed externally and processed for gross external, visceral and skeletal examinations. A high rate of maternal mortality; reduced gestation body weight, gestation body weight changes and food consumption; decreased corrected body weight and corrected weight gain were observed at 17.5/10 mg/kg bw/day. Fetal weight was also reduced at 17.5/10 mg/kg bw/day. There were no maternal deaths, clinical signs or body weight effects that were considered related to sodium azide at 1 and 5 mg/kg bw/day. No increase in the incidence of malformations and variations were observed at any of the doses evaluated. Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) and the Lowest Observed Adverse Effect Level (LOAEL) for maternal and developmental toxicity of sodium azide in rats were considered to be 5 and 10 mg/kg bw/day, respectively. The decrease in fetal weight coincided with maternal signs of clinical toxicity that included decreased activity, prostration, loss of righting reflex, lacrimation, impaired limb function, swelling (head and face), moribundity, difficult/slow/shallow breathing, and mortality. The decrease in fetal weight could be the result of dams decreasing food intake as a result of the clinical signs toxicity. This study clearly shows that embryo-fetal toxicity occurs only at doses that are toxic to the dams and, due to the lack of an adverse effect at the other doses, shows that sodium azide does not have an effect on the development of the fetuses.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.